- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03819634
Longevity of Multi-Slitted Catheter With Lantern Technology (Lantern)
Longevity of Multi-Slitted Catheter, the Convatec Inset II With Lantern Technology
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot study to obtain preliminary data to determine the time to set failure when the Lantern infusion set is worn for up to 10 days. The study is not intended for registration purposes or to support a 510(k) submission. The study will be conducted at one site: Stanford University.
This study will enroll 24 subjects (as per FDA approval) to establish the maximum length of Lantern infusion set wear when 80% of sets are still functional (excluding accidental "pull-outs"). Each participant will place the set and wear it for 10 days or until set failure and data will be collected on the cause of set failure. If a set is accidentally pulled out, it can be replaced by the subject. Failures are based on:
- Presence of serum ketones with hyperglycemia
- Unexplained hyperglycemia
- Signs of infection at the infusion site
- Pump occlusion alarm
- Adhesive failure
Since infusion set failures will occur after variable lengths of wear, regularly scheduled visits are unlikely to capture the day of an infusion set failure. Instead the subject will be taught how to insert the set, measure erythema and induration with a ruler marked in millimeters and to take a picture of the infusion site. Subjects will be instructed to text the study team when they remove their infusion set and to send a picture of the infusion site and measurements. If there is any evidence of an infection (≥10 mm of erythema or induration), they will be asked to come in that day for an unscheduled visit.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Palo Alto, California, United States, 94305
- Stanford
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Type 1 Diabetes by clinical definition
- Age 22 and over
- On tethered insulin pump therapy for at least 3 months using Lispro or Aspart insulin.
- Hemoglobin A1c level less than or equal to 9%
- Eating more than 60 grams of carbohydrate each day
- For females, not currently known to be pregnant
- Understanding and willingness to follow the protocol and sign informed consent
- Willingness to wear the experimental infusion sets
- Willingness to have photographs taken of their infusion sites
- Ability to speak, read and write in the language of the investigators
Exclusion Criteria:
The presence of any of the following is an exclusion for the study:
- Diabetic ketoacidosis in the past 3 months
- Severe hypoglycemia resulting in seizure or loss of consciousness within 3 months prior to enrollment
- Pregnant or lactating
- Known tape allergies
- Active infection
- A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol
- Known cardiovascular events in the last 6 months
- Known acute proliferative diabetic retinopathy
- Known adrenal disorder
- Current treatment for a seizure disorder
- Inpatient psychiatric treatment in the past 6 months
- Lack of stability on medication 1 month prior to enrollment including antihypertensive, thyroid, anti-depressant or lipid lowering medication.
- Use of SGLT inhibitor
- Suspected drug or alcohol abuse
- Dialysis or end stage kidney disease
Note: Adequately treated thyroid disease and celiac disease do not exclude subjects from enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lantern infusion set
Multi-slitted lantern infusion set
|
Each participant will insert the Inset II with Lantern technology and wear it for 10 days or until set failure and data will be collected on the cause of set failure.
The infusion set will be used with their usual insulin pump.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Infusion Set Failure
Time Frame: 10 days of infusion set wear
|
Time to when the infusion set fails and needs to be replaced.
|
10 days of infusion set wear
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Bruce A Buckingham, MD, Stanford University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB #45812
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Insulin Dependent Diabetes Mellitus 1
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
DreaMed DiabetesCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusIsrael
-
National Institute of Diabetes and Digestive and...Completed
-
Xeris PharmaceuticalsCompletedDiabetes Mellitus, Type 1 | Insulin-dependent Diabetes MellitusUnited States
-
Wayne State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes Mellitus, Insulin DependentUnited States
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedDiabetes Mellitus | Insulin-dependent Diabetes MellitusUnited States
-
The University of Texas Health Science Center,...National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
Clinical Trials on Inset II with Lantern Technology
-
ConvaTec Inc.UnknownColostomy | Ileostomy | UrostomyPoland
-
Kaohsiung Medical University Chung-Ho Memorial...Recruiting
-
Weill Medical College of Cornell UniversityNational Institute of Mental Health (NIMH)CompletedDepression | Anxiety | Depression in Old Age | Elder AbuseUnited States
-
Washington University School of MedicineNational Institute of Neurological Disorders and Stroke (NINDS)Active, not recruitingCervical Spondylotic MyelopathyUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Reproductive & Genetic Hospital of CITIC-XiangyaTerminated
-
Paola PisaniI.R.C.C.S Ospedale Galeazzi-Sant'AmbrogioRecruiting
-
Biotronik SE & Co. KGIrmandade Santa Casa de Misericórdia de Porto AlegreRecruiting
-
McMaster UniversityMcMaster Institute for Research on Aging; Physiotherapy Foundation of CanadaUnknownMuscle Weakness | Aging | Fall | Mobility Limitation
-
BSP Biological Signal Processing Ltd.Unknown